Quinones are compounds frequently contained in medicinal plants used for the treatment of inflammatory diseases. Therefore, the impact of plant-derived quinones on the arachidonic acid metabolic pathway is worthy of investigation. In this study, twenty-three quinone compounds of plant origin were tested in vitro for their potential to inhibit leukotriene B 4 (LTB 4 ) biosynthesis in activated human neutrophil granulocytes with 5-lipoxygenase (5-LOX) activity. The benzoquinones primin (3) and thymohydroquinone (4) (IC 50 = 4.0 and 4.1 µM, respectively) showed activity comparable with the reference inhibitor zileuton (IC 50 = 4.1 µM). Moderate activity was observed for the benzoquinone thymoquinone (2) (IC 50 = 18.2 µM) and the naphthoquinone shikonin (1) (IC 50 = 24.3 µM). The anthraquinone emodin and the naphthoquinone plumbagin (5) displayed only weak activities (IC 50 > 50 µM). The binding modes of the active compounds were further evaluated in silico by molecular docking to the human 5-LOX crystal structure. This process supports the biological data and suggested that, although the redox potential is responsible for the quinone's activity on multiple targets, in the case of 5-LOX the molecular structure plays a vital role in the inhibition. The obtained results suggest primin as a promising compound for the development of dual COX-2/5-LOX inhibitors.
Natural quinones are found in various herbs used for the treatment of inflammatory diseases in traditional medicinal systems. For example, the roots of Lithospermum erythrorhizon Siebold & Zucc., used in traditional Chinese medicine (known as tzu ts'ao) for the preparation of antiseptic and anti-inflammatory ointments, yield shikonin (1), a naphthoquinone with potent in vitro and in vivo antiinflammatory effects [1] [2] [3] . The seeds of Nigella sativa L., popular in Mediterranean and Middle East countries as a spice and traditional remedy for various ailments, including asthma and rheumatism, have a high content of thymoquinone (2) [4] . The anti-inflammatory activity of this benzoquinone is, besides other modes of action, explained by inhibition of 5-LOX [5, 6] . Similarly to compound 2, several other quinones of plant origin were also found to be 5-LOX inhibitors [7] [8] [9] . Moreover, recently, inhibition of LTB 4 biosynthesis in rat neutrophils by the active principle component of tzu ts'ao, acetylshikonin [10] , and inhibition of cysteinyl-leukotrienes biosynthesis in rat basophilic leukemia-1 cells by emodin from Rheum tanguticum Maxim. ex Balf. was recorded [11] . According to these previous findings, plant-derived quinones as potential inhibitors of the arachidonic acid cascade are worthy of a more detailed investigation.
This study focuses on the inhibition of 5-LOX activity, which is responsible for the biosynthesis of leukotrienes, potent mediators of chronic inflammatory diseases such as asthma, allergic reactions, and atherosclerosis [12] . Currently, dual inhibition of 5-LOX and cyclooxygenase-2 (COX-2), which is another important proinflammatory enzyme, is proposed as a promising approach in the treatment of inflammatory diseases with less side effects compared with treatment by COX-2 specific or non-specific inhibitors [13, 14] .
In our previous study, we explored the effect of plant quinones on cyclooxygenase-1 (COX-1) and COX-2 activity in vitro. Several naphthoquinones and benzoquinones showed interesting activity [15] . In the present study, the 23 quinone compounds of plant origin, previously assessed for COX inhibition, were tested for inhibition of leukotriene B 4 (LTB 4 ) biosynthesis using activated human neutrophil granulocytes with 5-LOX activity. The most active compounds were further evaluated in silico with docking experiments to propose a molecular mode of action.
Compounds 3 and 4 ( Figure 1 ) showed the best ability to inhibit LTB 4 production in human neutrophil granulocytes stimulated by calcium inonophore A23187, while moderate activity was recorded for compounds 2 and 1 (Figure 1) , with respective IC 50 values of 4.0 (+ 1.6), 4.1 (+ 2.6), 18.2 (+ 8.2), and 24.3 (+ 8.0) µM. Weak activity (more than 30%, but less than 50% inhibition of LTB 4 production at 50 µM concentration) was observed for emodin and (6), inactive juglone (7) , and inactive shikonin enantiomer alkannin (8) . plumbagin (5) ( Figure 1 ). Other tested quinone compounds (benzoquinones: embelin, arbutin; napthoquinones: juglone, 7-methyljuglone, lawsone, phylloquinone, alkannin, lapachol, diospyrin; anthraquinones: purpurin, aloe-emodin, chrysophanol, rhein, diacetyl rhein, damnacanthal, frangulin A, frangulin B) showed no activity at 50 µM concentration. The specific 5-LOX inhibitor zileuton [16] had an IC 50 value of 4.1 + 2.0 µM.
Inhibition of 5-LOX by compound 2 was previously reported in rat peritoneal leukocytes [5, 17] and human granulocytes [6] . In our assay, 2 showed weaker activity than its hydroquinone form 4. This could be explained by the proposed inhibitory mechanism suggesting that quinones are first reduced by reductases and then the hydroquinone form inhibits 5-LOX activity via a reduction of the active site iron, as was described for 2,3,5-trimethyl-6-(3pyridylmethyl)-1,4-benzoquinone [18] . Moreover, the better solubility (water solubility estimate from fragments for: compound 4 = 5884.9 mg/L, compound 2 = 542.69 mg/L) [19] in the aqueous environment can also contribute to the higher activity of the reduced form.
To further elucidate the mode of inhibition, the active compounds, as well as structurally related but inactive quinones, were docked with two software packages. The analysis of the interaction patterns corresponded well with the experimental findings and suggested the following binding poses in the binding pocket: While it was not possible to distinguish the inactive juglone (7) from the weakly active 5 (Figure 1 ), a comparison between the active 1 and its inactive enantiomer alkannin (8) showed a preference for the active compound ( Figure 2A ). While both compounds displayed a good fit into the hydrophobic binding pocket and several hydrophobic interactions, no docking poses with polar interactions for compound 8 were found. The active compound 1 though showed a hydrogen bond to His367 (Figure 2A ), which is one of the amino acids coordinating the catalytic iron [20] . This stabilized position close to the catalytic center could explain why 1 is active in comparison with 8. The docking poses for compound 3 resembled those of the structurally related, selective and orally active 5-LOX inhibitor AA-861 (6) [21, 22] with IC 50 = 0.8 µM [23] , and suggested a binding mode ( Figure 2B ) including a hydrogen bond to His367 and several hydrophobic interactions with the amino acids forming the binding pocket. The difference in activity could result from the longer apolar chain residue of compound 6, which fills the hydrophobic channel for the fatty acid substrate of 5-LOX to a larger extent. In addition, compound 6 shows a second H-bond to Ile415. This suggests that a prolonged hydrophobic residue could enhance the inhibitory activity. (6) (green) and the tested compound primin (3) (blue). Protein-ligand interactions are visualized as yellow spheres (hydrophobic contacts), red arrows (hydrogen bond acceptors), and green arrows (hydrogen bond donors).The interaction pattern of compound 3 consists of a hydrogen bond between His367 and the quinone oxygen and of a hydrophobic feature at the end of the side chain. The protein-ligand contacts between compound 6 and 5-LOX consist of the same hydrogen bond with His367 as well as two hydrophobic contacts at the side chain, as well as a hydrogen bond to Ile415.
In summary, compounds 3 and 4 were potent 5-LOX inhibitors with similar activity to the reference inhibitor zileuton in isolated human neutrophils. These results, together with the molecular docking study, suggest that, although the redox potential of quinone compounds plays a vital role in their activity, their 3D structure is important for their ability to access the catalytic center of 5-LOX. The redox potential alone cannot explain either the inactivity of many of the tested compounds on 5-LOX or the previously reported strong COX-2 selectivity of compound 3 [15] . Compound 3 is thus a promising lead structure for new dual COX-2/5-LOX inhibitors. Due to its allergenicity [24] , optimization of the structure, maintaining its COX/LOX inhibitory properties and improving the toxicological profile, would be an interesting perspective in the development of a primin derivative as a potent and well tolerated inhibitor of eicosanoid biosynthesis. Currently, derivatives of compound 3 are being designed according to the docking studies
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Experimental
Reagents: Diospyrin and 7-methyljuglone were obtained from Wageningen University. Alkannin, chrysophanol, damnacanthal, diacetyl rhein, frangulin A, frangulin B, primin, and shikonin were purchased from Chromadex. Sodium chloride (NaCl), potassium chloride (KCl), magnesium chloride hexahydrate (MgCl 2 .6H 2 O), and sodium hydroxide (NaOH) were purchased from Lachema a.s. Aloe-emodin, arbutin, carminic acid, embelin, emodin, juglone, lawsone, lapachol, plumbagin, phylloquinone, purpurin, rhein, thymoquinone, eicosatetraynoic acid (ETYA), ethanol (EtOH), calciumionophor A23187, dimethylsulfoxide (DMSO), arachidonic acid (AA), water-free D-glucose, trypan blue, and gentian violet were from Sigma-Aldrich. Dextran T-500 was purchased from Roth, and calcium chloride (CaCl 2 .2H 2 O) and acetic acid (CH 3 COOH) from Penta. Ammonium chloride (NH 4 Cl) was purchased from Lachner s.r.o. and zileuton was donated by Farmak a.s. Tris was purchased from Bio-Rad. Thymohydroquinone was prepared by the reduction of thymoquinone, as described by Tesarova et al. [25] . Purity of the compounds tested for COX inhibition was 95.0% or higher except of shikonin (purity = 92.7%) and emodin (90.0%).
5-Lipoxygenase assay:
The assay was performed according to the procedure previously described by Adams et al. [26] , with slight modifications. Venous human blood (45 mL) obtained from healthy donors was sedimented in 20 mL of dextran solution (6% dextran T-500, 1% NaCl) at 4ºC. After 1 h, supernatant was collected and centrifuged at 1600 rpm at 4ºC for 10 min and then the supernatant was discarded. The obtained pellet was washed (7.4% CaCl 2 dihydrate, 0.1% anhydrous D-glucose, 0.2% MgCl 2 .6H 2 O, 0.04% KCl, 1.75% Tris, pH 7.6) and again centrifuged. The hereby obtained pellet was lysed (0.17% NH 4 Cl, 0.2% Tris, pH 7.2) for 5 min at room temperature and then centrifuged at 1400 rpm at 4ºC for 5 min. The pellet was washed and centrifuged at 1400 rpm at 4ºC for 15 min. Finally, the pellet was dissolved in 3 mL of assay solution (1.75% Tris, 0.9% NaCl, pH 7.4) and the cells tested for viability. The cells were diluted to the final concentration of 4500 cells/µL.
The incubation mixture consisted of 225 µL of the cell suspension, 10 µL of 2 mM CaCl 2 , 10 µL of 10 µM ETYA, 5 µL of tested substances dissolved in DMSO, 10 µL of 21 µM calcium ionophor A23187, and 5 µL of 120 µM arachidonic acid. The reaction was stopped after 10 min incubation at 37ºC by 20 µL of 10% formic acid. Samples were diluted 40 times in ELISA buffer and the concentration of LTB 4 was measured using a commercial LTB 4 ELISA kit (Enzo Life Sciences) according to the manufacturer's instructions. Absorbance relative to LTB 4 concentration was measured at 405 nm using a Tecan Infinite M200 (Tecan Group).
The results were expressed as percentage inhibition of LTB 4 formation against untreated samples (blanks). At least 3 concentrations were used for the calculation of IC 50 values. Three independent experiments with at least 2 replicates were used for the calculation of inhibition curves.
Docking:
The software AutoDock Vina 1.1.2 [27] was set to calculate up to 9 binding poses for each compound. There is only one published crystal structure of 5-LOX in the Protein Data Bank (PDB; www.pdb.org) [28] at the time of this study (PDB code 3o8y) [20] and it does not contain a ligand. To define the grid box where the docking should calculate suitable binding poses, the homologous 3-LOX co-crystallized with epigallocatechin (PDB entry 1jnq) [29] was aligned with 5-LOX with PyMOL, 0.99rc6 (DeLano Scientific LLC:2006). The position of epigallocatechin close to the non-heme catalytic iron was set as the center of the grid box (coordinates -0.112, 23.915, -0.703).
The binding cavity near the catalytic iron is about 13 Å long, 10 Å wide, and 6 Å high. It is defined by the amino acids Trp147, Phe177, Tyr181, Asn407, Thr364, Leu420, Phe421, His432, Trp599, His600, and Ala603. A conformational change in the active enzyme upon ligand binding is likely since in the 5-LOX crystal structure the passage into the active site cavity is blocked [20] , so it was vital to define the grid box in a way that allowed the ligands to enter the active site. After preliminary experiments with the reference inhibitor zileuton the grid box was defined as a 26 x 26 x 26 Å cube, allowing molecules to enter the binding site, but also large enough so the program could reject molecules with a bad fit and place them outside.
To evaluate the suitability of the crystal structure and the docking workflow, 5 different reference inhibitors found in literature [8] were docked. Zileuton (also tested in the present study) and BW A4C were used as examples of iron chelators, L 697 as a non-redox type inhibitor, AA-861 as a redox type inhibitor, and licofelone as a dual inhibitor of COX and 5-LOX. For all 5 compounds mainly poses inside the binding pocket were generated by the software. Furthermore, docking was performed for inactive compounds from each group of quinones (benzoquinones. 3 Å diameter of the planar ring system, naphthoquinones: 6 Å diameter, and anthraquinones: 10 Å diameter) to test the predictive power of the docking and to study structure activity relationships. The vast majority of docking poses generated for the large, inactive anthraquinone compounds placed them outside the binding pocket. Naphtoquinones and benzoquinones could not be distinguished by their placement, but for the active compounds, more probable binding poses were produced. Additional docking experiments were performed with Maestro Glide (version 5.7, Schrödinger, Inc., 2011) under the same conditions. The ligands were prepared in LigPrep (version 2.5, Schrödinger, Inc., 2011). Binding site visualization and interaction pattern analysis was executed with LigandScout 3.02 [30] .
